Company Update: Gilead Sciences Inc (NASDAQ:GILD) – Gilead Announces Phase 1 Data for Investigational Therapy, GS-6615, in Patients with Long QT-3 Syndrome

[Business Wire] – Gilead Sciences, Inc. today announced results from a Phase 1 clinical trial of GS-6615, an investigational, selective late sodium current inhibitor, showing a shortening of the QTc interval in patients . . . → Read More: Company Update: Gilead Sciences Inc (NASDAQ:GILD) – Gilead Announces Phase 1 Data for Investigational Therapy, GS-6615, in Patients with Long QT-3 Syndrome Similar Articles: Company Update: Gilead Sciences Inc (NASDAQ:GILD) – Gilead Sciences Announces First Quarter 2014 Financial Results Merck & Co. Inc. (NYSE:MRK) – 8:31 am Merck initiates rolling submission of U.S. Biologics License Application for MK-3475, an investigational Anti-PD-1 Immunotherapy, in patients with advanced melanoma; expects to complete application in 1H14 Company Update – Biogen Idec Inc. (NASDAQ:BIIB) – Sobi’s partner Biogen Idec to present phase 3 data on prolonged half-life of Haemophilia candidates in young children at annual ASH meeting